ARAV - Aravive Inc Stock Price, Fair Value and News

$0.04

Market Closed

ARAV Stock Valuation Analysis

Valuation

Max Portfolio %

ARAV Price Action

ARAV RSI Chart

ARAV Stock Valuation Analysis

Valuation

Max Portfolio %

ARAV Valuation

ARAV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ARAV Fundamentals

ARAV Revenue

ARAV Earnings

ARAV Profitability

ARAV Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	9.5M	9.2M	7.0M	0
2022	8.3M	6.1M	8.6M	9.1M
2021	6.1M	6.6M	7.0M	7.4M
2020	0	0	0	5.7M
2019	25.9M	18.9M	11.8M	4.8M
2018	0	0	0	33.0M
2017	0	0	0	40.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Aravive Inc

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

CEO	Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D.
WEBSITE	https://aravive.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	23